Company intelligence / Profile preview

Diafir

Rennes, Brittany, Francediafir.com ↗

Ownership: Private
Development stage: Clinical

Overview

DIAFIR’s SPID™ platform enables rapid, minimally invasive blood-based diagnosis of NASH and infectious arthropathies. The company’s lead product, the NASHMIR® serum test for early detection of NASH, has shown promising results in clinical studies and aims to become a first-line screening tool. The Synofresh study validated their approach in septic arthritis with high confidence exclusion of non-infected patients. Regulatory approval was targeted post-clinical validation.

Therapeutic areas: GastroenterologyMetabolic DisordersInfectious Diseases
Modalities: Device (diagnostic platform)Non-pharmacological therapy (diagnostic test)
Industry: Metabolite Diagnostics

Partnerships

No major pharmaceutical partnerships disclosed; collaborations with French hospitals/universities on clinical studies.

Beyond the preview

Go deeper on Diafir.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diafir.

Explore the full profile